Target
IL13Rα2
1 abstract
Abstract
EO2401 (E) peptide immunotherapy + nivolumab (N) +/- bevacizumab (B) in recurrent glioblastoma (GB): EOGBM1-18/ROSALIE.Org: Universitätsklinikum Heidelberg, German Cancer Research Center, Sorbonne Université, AP-HP at Saint-Louis Hospital, ICM,